2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer

被引：7
作者：
So, Alan, I [1 ]
Chi, Kim [2 ]
Danielson, Brita [3 ]
Fleshner, Neil E. [4 ]
Kinnaird, Adam [5 ]
Kapoor, Anil [6 ]
Niazi, Tamim [7 ]
Pouliot, Frederic [8 ]
Rendon, Ricardo A. [9 ]
Shayegan, Bobby [6 ]
Sridhar, Srikala S. [10 ]
Vigneault, Eric [11 ]
Saad, Fred [12 ]
机构：
[1] Univ British Columbia, Dept Urol Sci, Vancouver, BC, Canada
[2] BC Canc, Vancouver, BC, Canada
[3] Univ Alberta, Dept Oncol, Div Radiat Oncol, Edmonton, AB, Canada
[4] Univ Toronto, Dept Surg, Div Urol, Toronto, ON, Canada
[5] Univ Alberta, Dept Surg, Div Urol, Edmonton, AB, Canada
[6] McMaster Univ, Dept Surg, Div Urol, Hamilton, ON, Canada
[7] McGill Univ, Dept Oncol, Div Radiat Oncol, Montreal, PQ, Canada
[8] Univ Laval, Dept Surg, Div Urol, Quebec City, PQ, Canada
[9] Dalhousie Univ, Dept Urol, Halifax, NS, Canada
[10] Univ Toronto, Princess Margaret Canc Ctr, Div Med Oncol, Toronto, ON, Canada
[11] Univ Laval, CHUQ, Dept Radiat Oncol, Quebec City, PQ, Canada
[12] Univ Montreal, Dept Surg, Div Urol, Montreal, PQ, Canada
来源：
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL | 2022年 / 16卷 / 12期
关键词：
ANDROGEN-DEPRIVATION THERAPY; RANDOMIZED CONTROLLED-TRIAL; INCREASED SURVIVAL; ZOLEDRONIC ACID; PLUS PREDNISONE; BONE LOSS; MEN; ENZALUTAMIDE; DOCETAXEL; ABIRATERONE;
D O I：
10.5489/cuaj.8148
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：E581 / E589
页数：9
相关论文
共 47 条
  • [11] Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
    Chi, Kim N.
    Agarwal, Neeraj
    Bjartell, Anders
    Chung, Byung Ha
    Pereira de Santana Gomes, Andrea J.
    Given, Robert
    Juarez Soto, Alvaro
    Merseburger, Axel S.
    Ozguroglu, Mustafa
    Uemura, Hirotsugu
    Ye, Dingwei
    Deprince, Kris
    Naini, Vahid
    Li, Jinhui
    Cheng, Shinta
    Yu, Margaret K.
    Zhang, Ke
    Larsen, Julie S.
    McCarthy, Sharon
    Chowdhury, Simon
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (01) : 13 - 24
  • [12] Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
    Clarke, N. W.
    Ali, A.
    Ingleby, F. C.
    Hoyle, A.
    Amos, C. L.
    Attard, G.
    Brawley, C. D.
    Calvert, J.
    Chowdhury, S.
    Cook, A.
    Cross, W.
    Dearnaley, D. P.
    Douis, H.
    Gilbert, D.
    Gillessen, S.
    Jones, R. J.
    Langley, R. E.
    MacNair, A.
    Malik, Z.
    Mason, M. D.
    Matheson, D.
    Millman, R.
    Parker, C. C.
    Ritchie, A. W. S.
    Rush, H.
    Russell, J. M.
    Brown, J.
    Beesley, S.
    Birtle, A.
    Capaldi, L.
    Gale, J.
    Gibbs, S.
    Lydon, A.
    Nikapota, A.
    Omlin, A.
    O'Sullivan, J. M.
    Parikh, O.
    Protheroe, A.
    Rudman, S.
    Srihari, N. N.
    Simms, M.
    Tanguay, J. S.
    Tolan, S.
    Wagstaff, J.
    Wallace, J.
    Wylie, J.
    Zarkar, A.
    Sydes, M. R.
    Parmar, M. K. B.
    James, N. D.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (12) : 1992 - 2003
  • [13] Committee CCSA, 2019, CAN CANC STAT 2018
  • [14] Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial
    Connor, Martin John
    Shah, Taimur Tariq
    Smigielska, Katarzyna
    Day, Emily
    Sukumar, Johanna
    Fiorentino, Francesca
    Sarwar, Naveed
    Gonzalez, Michael
    Falconer, Alison
    Klimowska-Nassar, Natalia
    Evans, Martin
    Naismith, Olivia Frances
    Thippu Jayaprakash, Kamalram
    Price, Derek
    Gayadeen, Shiva
    Basak, Dolan
    Horan, Gail
    McGrath, John
    Sheehan, Denise
    Kumar, Manal
    Ibrahim, Azman
    Brock, Cathryn
    Pearson, Rachel A.
    Anyamene, Nicola
    Heath, Catherine
    Shergill, Iqbal
    Rai, Bhavan
    Hellawell, Giles
    McCracken, Stuart
    Khoubehi, Bijan
    Mangar, Stephen
    Khoo, Vincent
    Dudderidge, Tim
    Staffurth, John Nicholas
    Winkler, Mathias
    Ahmed, Hashim Uddin
    [J]. BMJ OPEN, 2021, 11 (02):
  • [15] Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
    Davis, Ian D.
    Martin, Andrew J.
    Stockler, Martin R.
    Begbie, Stephen
    Chi, Kim N.
    Chowdhury, Simon
    Coskinas, Xanthi
    Frydenberg, Mark
    Hague, Wendy E.
    Horvath, Lisa G.
    Joshua, Anthony M.
    Lawrence, Nicola J.
    Marx, Gavin
    McCaffrey, John
    McDermott, Ray
    McJannett, Margaret
    North, Scott A.
    Parnis, Francis
    Parulekar, Wendy
    Pook, David W.
    Reaume, M. Neil
    Sandhu, Shahneen K.
    Tan, Alvin
    Tan, T. Hsiang
    Thomson, Alastair
    Tu, Emily
    Vera-Badillo, Francisco
    Williams, Scott G.
    Yip, Sonia
    Zhang, Alison Y.
    Zielinski, Robert R.
    Sweeney, Christopher J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (02) : 121 - 131
  • [16] Abiraterone and Increased Survival in Metastatic Prostate Cancer
    De Bono, Johann S.
    Logothetis, Christopher J.
    Molina, Arturo
    Fizazi, Karim
    North, Scott
    Chu, Luis
    Chi, Kim N.
    Jones, Robert J.
    Goodman, Oscar B., Jr.
    Saad, Fred
    Staffurth, John N.
    Mainwaring, Paul
    Harland, Stephen
    Flaig, Thomas W.
    Hutson, Thomas E.
    Cheng, Tina
    Patterson, Helen
    Hainsworth, John D.
    Ryan, Charles J.
    Sternberg, Cora N.
    Ellard, Susan L.
    Flechon, Aude
    Saleh, Mansoor
    Scholz, Mark
    Efstathiou, Eleni
    Zivi, Andrea
    Bianchini, Diletta
    Loriot, Yohann
    Chieffo, Nicole
    Thian Kheoh
    Haqq, Christopher M.
    Scher, Howard I.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) : 1995 - 2005
  • [17] Egerdie B, 2010, CUAJ-CAN UROL ASSOC, V4, P129
  • [18] BONE-MINERAL DENSITY IN PATIENTS WITH PROSTATIC-CANCER TREATED WITH ORCHIECTOMY AND WITH ESTROGENS
    ERIKSSON, S
    ERIKSSON, A
    STEGE, R
    CARLSTROM, K
    [J]. CALCIFIED TISSUE INTERNATIONAL, 1995, 57 (02) : 97 - 99
  • [19] Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design
    Fizazi, Karim
    Foulon, Stephanie
    Carles, Joan
    Roubaud, Guilhem
    McDermott, Ray
    Flechon, Aude
    Tombal, Bertrand
    Supiot, Stephane
    Berthold, Dominik
    Ronchin, Philippe
    Kacso, Gabriel
    Gravis, Gwenaelle
    Calabro, Fabio
    Berdah, Jean-Francois
    Hasbini, Ali
    Silva, Marlon
    Thiery-Vuillemin, Antoine
    Latorzeff, Igor
    Mourey, Loic
    Laguerre, Brigitte
    Abadie-Lacourtoisie, Sophie
    Martin, Etienne
    El Kouri, Claude
    Escande, Anne
    Rosello, Alvar
    Magne, Nicolas
    Schlurmann, Friederike
    Priou, Frank
    Chand-Fouche, Marie-Eve
    Freixa, Salvador Villa
    Jamaluddin, Muhammad
    Rieger, Isabelle
    Bossi, Alberto
    [J]. LANCET, 2022, 399 (10336) : 1695 - 1707
  • [20] Abiraterone acetate plus prednisone in patients with newly Croatia& diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
    Fizazi, Karim
    NamPhuong Tran
    Fein, Luis
    Matsubara, Nobuaki
    Rodriguez-Antolin, Alfredo
    Alekseev, Boris Y.
    Ozguroglu, Mustafa
    Ye, Dingwei
    Feyerabend, Susan
    Protheroe, Andrew
    Sulur, Giri
    Luna, Yesenia
    Li, Susan
    Mundle, Suneel
    Chi, Kim N.
    [J]. LANCET ONCOLOGY, 2019, 20 (05) : 686 - 700
12345